Tretinoin · Regulatory approval

FDA approval: Tretinoin

U.S. Food and Drug Administration · May 14, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a generic topical tretinoin gel 0.08% formulation (Amneal) on 14 May 2026 under an original ANDA submission. This is a regulatory action record that does not contain clinical trial data, efficacy results, or safety comparisons.

What was studied

Regulatory approval. Intervention: Tretinoin gel 0.08% topical formulation.

Key findings

FDA approval granted for tretinoin gel 0.08% topical formulation by Amneal on 2026-05-14

Safety

This record does not contain clinical trial results, efficacy data, or safety outcomes. No adverse event profile or patient population studied is disclosed in this regulatory record.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA approval of a generic topical tretinoin formulation; regulatory action, not clinical evidence of efficacy or safety.

Study design

As stated by the source record.

InterventionTretinoin gel 0.08% topical formulation

Reported figures

Quoted from the source exactly as published.

Strength0.08%

FormulationGel, topical

Approval date2026-05-14

Caveats

This record does not contain clinical trial results, efficacy data, or safety outcomes.
No comparative bioavailability or bioequivalence data are reported.
No adverse event profile or patient population studied is disclosed in this regulatory record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record; no clinical trial design reported.

Directness

insufficient

Approval record does not report clinical outcomes or direct evidence.

Consistency

insufficient

Single regulatory action; no comparative data reported.

Risk of bias

insufficient

Regulatory record; no trial methodology or bias assessment reported.

Sample adequacy

insufficient

Regulatory record; no sample size or population data reported.

Source abstract

Drugs@FDA record for application ANDA217497. This is a regulatory action record, not a clinical study. Brand name: TRETINOIN. Active ingredient: TRETINOIN. Sponsor: AMNEAL. Submission type: ORIG (original application). Approval status date: 2026-05-14. Products: TRETINOIN, GEL, TOPICAL, TRETINOIN 0.08%.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

TretinoinAmneal